Please use this identifier to cite or link to this item:
Title: Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
Austin Authors: Dhiman, Kunal;Gupta, Veer Bala;Villemagne, Victor L ;Eratne, Dhamidhu;Graham, Petra L;Fowler, Christopher;Bourgeat, Pierrick;Li, Qiao-Xin;Collins, Steven;Bush, Ashley I;Rowe, Christopher C ;Masters, Colin L ;Ames, David;Hone, Eugene;Blennow, Kaj;Zetterberg, Henrik;Martins, Ralph N
Affiliation: Centre for Economic Impacts of Genomic Medicine (GenIMPACT) Macquarie University Sydney NSW Australia
Academic Unit for Psychiatry of Old age St. George's Hospital The University of Melbourne Australia
KaRa Institute of Neurological Diseases Sydney NSW Australia
Centre of Excellence in Alzheimer's Disease Research and Care School of Medical and Health Sciences Edith Cowan University Joondalup WA Australia
Co-operative Research Centre for Mental Health Carlton Victoria Australia
Australian Alzheimer's Research Foundation Ralph and Patricia Sarich Neuroscience Research Institute Nedlands WA Australia
Department of Biomedical Sciences Macquarie University Sydney NSW Australia
School of Psychiatry and Clinical Neurosciences University of Western Australia Perth WA Australia
Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden
Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology Queen Square London UK
UK Dementia Research Institute at UCL London UK
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden
National Ageing Research Institute Parkville Victoria Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Florey Institute of Neuroscience and Mental Health Parkville Victoria Australia
Melbourne Neuropsychiatry Centre University of Melbourne and NorthWestern Mental Health Parkville Victoria Australia
CSIRO Health and Biosecurity Brisbane Australia
School of Medicine Deakin University Victoria Australia
Department of Medicine University of Melbourne Melbourne Victoria Australia
Issue Date: 27-Feb-2020
Date: 2020-02-27
Publication information: Alzheimer's & dementia (Amsterdam, Netherlands) 2020; 12(1): e12005
Abstract: This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.
DOI: 10.1002/dad2.12005
ORCID: 0000-0002-5832-9875
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
PubMed URL: 32211500
ISSN: 2352-8729
Type: Journal Article
Subjects: ELISA
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Mar 4, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.